Research To Practice | Oncology Videos

Featuring an interview with Dr Joyce O'Shaughnessy , including the following topics: Overview of CDK Inhibition for Metastatic Breast Cancer (0:00) Features of High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer (7:45) Sequencing and Selection of CDK4/6 Inhibitors (23:28) Management of Toxicities Associated with CDK Inhibitors and Promoting Patient Adherence (45:47) Review of Clinical In...

Featuring perspectives from Dr Matthew Gubens , including the following topics: Introduction: Risk of Autoimmune Toxicity with Checkpoint Inhibitors (0:00) Immunotherapy in the Neoadjuvant/Adjuvant Setting (7:33) Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (15:45) First-Line Immunotherapy for Metastatic NSCLC (24:04) Novel Agents and Strategies (30:39) Immunotherapy for N...

Featuring an interview with Dr Matthew R Smith , including the following topics: Selection and sequencing of androgen-targeting therapies (0:00) Evidence-based selection of treatment for metastatic hormone-sensitive prostate cancer (25:07) New considerations with the use of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) (27:44) Role of novel radiopharmaceuticals for mC...

Featuring an interview with Dr Kimberly H Allison , including the following topics: Contemporary practices in pathology and reporting biomarkers of interest (0:00) HER2 testing across numerous solid tumor types (2:47) ER-low reporting category and pathologic interpretation (6:28) PD-1/PD-L1 testing methodology and challenges with bone biopsies (10:53) CME information and select publications

Featuring a slide presentation and related discussion from Dr Kimberly H Allison , including the following topics: Pathological assessment of HER2 and appropriate testing methodologies (0:00) Effect of the DESTINY-Breast04 study on clinical practice (12:32) Relevancy of HER2-ultralow expression and implications of the DESTINY-Breast06 study (22:53) Future directions in the pathological and clinica...

Featuring perspectives from Dr Dana M Chase , including the following topics: Introduction: ASCO 2024 Review (0:00) Ovarian Cancer (14:29) HER2 as a Therapeutic Target (29:18) Endometrial Cancer (38:55) Cervical Cancer (51:11) CME information and select publications

Featuring an interview with Dr Jonathan W Goldman , including the following topics: Contemporary and Future Care for Patients with Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation (0:00) Evolving First-Line Treatment for Metastatic NSCLC with an EGFR Mutation (21:05) Other Emerging Strategies for Relapsed Metastatic Lung Cancer (29:16) Emerging Role of Antibody-Drug Conjugate...

Featuring perspectives from Dr Nikhil I Khushalani and Dr Jason J Luke, including the following topics: Introduction (0:00) Evidence-Based Treatment of Nonmetastatic and Metastatic Melanoma — Dr Luke (2:49) Optimizing the Management of Nonmelanoma Skin Cancers — Dr Khushalani (36:54) CME information and select publications

Featuring perspectives from Dr Rana R McKay and Prof Thomas Powles , including the following topics: Introduction (0:00) Management of Metastatic Clear Cell Renal Cell Carcinoma (RCC) — Prof Powles (12:39) Treatment Approaches for Nonmetastatic RCC; Optimal Care of Patients with Non-Clear Cell RCC — Dr McKay (49:27) CME information and select publications

Featuring perspectives from Dr Scott Kopetz and Dr John Strickler , including the following topics: Introduction (0:00) Recent Therapeutic Advances in Colorectal Cancer (CRC) — Dr Strickler (1:53) New Developments in Targeted Therapy for Metastatic CRC — Dr Kopetz (35:11) CME information and select publications

Featuring perspectives from Dr Joshua Brody, Dr Ian W Flinn and Dr Tycel Phillips , including the following topics: Introduction: CD3 Bispecific Antibodies in the Community Oncology Setting (0:00) Integration of Bispecific Antibody Therapy into the Management of Diffuse Large B-Cell Lymphoma — Dr Phillips (18:13) Current and Future Role of Bispecific Antibodies in Follicular Lymphoma and Other B-C...

Featuring perspectives from Dr Kevin Kalinsky and Dr Heather McArthur , including the following topics: Introduction (0:00) Case: A woman in her mid 80s with a 2.7-cm residual tumor after neoadjuvant pembrolizumab/chemotherapy for localized triple-negative breast cancer (TNBC) — Ranju Gupta, MD (3:31) Question and Comments: Approach to neoadjuvant therapy and defining residual disease; PD-L1 statu...

Featuring perspectives from Dr Rafael Fonseca, Dr María-Victoria Mateos and Dr Elizabeth O'Donnell, moderated by Dr O'Donnell , including the following topics: Introduction (0:00) Treatment Approaches for Newly Diagnosed Multiple Myeloma (MM) — Dr Fonseca (2:05) Role of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies in the Care of Patients with MM — Dr Mateos (22:06) Incorporat...

Featuring perspectives from Dr Rebecca S Heist, Dr Luis Paz-Ares and Dr Jacob Sands, moderated by Dr Sands , including the following topics: Introduction (0:00) Integration of Antibody-Drug Conjugates (ADCs) into the Care of Patients with Non-Small Cell Lung Cancer (NSCLC) and HER2 Alterations — Dr Paz-Ares (1:28) Emerging Role of TROP2-Targeted ADCs for NSCLC — Dr Sands (23:12) Other Promising Ta...

Featuring perspectives from Dr Aaron T Gerds , including the following topics: Introduction: Myelofibrosis (MF) for Oncology "Newbies" (0:00) Biology of MF (5:20) Management of Anemia in MF (20:12) Novel Strategies for MF (29:28) Journal Club  (46:12) CME information and select publications

Featuring perspectives from Dr Neeraj Agarwal, Dr Emmanuel S Antonarakis, Dr Andrew J Armstrong, Dr Tanya B Dorff and Dr Matthew R Smith, moderated by Dr Armstrong , including the following topics: Introduction (0:00) Optimizing the Management of Nonmetastatic Prostate Cancer — Dr Dorff (3:34) Evidence-Based Selection of Treatment for Metastatic Hormone-Sensitive Prostate Cancer — Dr Smith (26:32)...

Featuring perspectives from Dr Aditya Bardia, Dr Harold J Burstein, Prof Giuseppe Curigliano, Dr Sara A Hurvitz, Dr Hope S Rugo and Dr Joyce O'Shaughnessy, moderated by Dr Rugo , including the following topics: Introduction (0:00) Optimizing the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Dr Hurvitz (4:38) Individualized Selection of Up-Front Therapy for Patients with HR-Positive,...

Featuring perspectives from Dr Floor J Backes, Dr Mansoor Raza Mirza, Dr Ritu Salani, Dr Angeles Alvarez Secord and Dr Brian M Slomovitz, with cases presented by Dr Eric H Lee, Dr Priya Rudolph and Dr Lyndsay J Willmott, moderated by Dr Secord , including the following topics: Up-Front Treatment for Advanced Ovarian Cancer (OC) — Dr Salani Introduction (0:00) Case: A woman in her mid 60s with deme...

Featuring perspectives from Ms Jamie Carroll, Ms Kelly EH Goodwin, Dr Erika Hamilton and Dr Hope S Rugo , including the following topics: Introduction (0:00) Overview of Antibody-Drug Conjugates (ADCs); HER2-Targeted ADCs for Breast Cancer — T-DM1, Trastuzumab Deruxtecan (7:22) The Incidence and Management of Interstitial Lung Disease with ADCs (34:05) ADCs Targeting Other Signaling Pathways in Br...

Featuring perspectives from Dr Robin K (Katie) Kelley, Dr Edward Kim and Prof Arndt Vogel, and moderated by Dr Kelley , including the following topics: Introduction (0:00) Recent Developments in the Management of Early- and Intermediate-Stage Hepatocellular Carcinoma (HCC) — Dr Kim (1:58) First-Line Therapy for Advanced HCC and Biliary Tract Cancers (BTCs) — Prof Vogel (22:24) Integration of Targe...

Featuring perspectives from Dr Jonathan W Goldman, Dr Corey J Langer, Dr Joel W Neal, Dr Zofia Piotrowska, Dr Joshua K Sabari and Dr Helena Yu, moderated by Dr Yu , including the following topics: Introduction (0:00) Contemporary Care for Patients with Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Dr Langer (2:08) Evolving First-Line Treatment for Metastatic NSCLC with a...

Featuring perspectives from Dr Harold J Burstein, Ms Kelly Fischer, Dr Komal Jhaveri and Ms Melissa Rikal , including the following topics: Introduction (0:00) The Utility of Genomic Assays in Treatment Decision-Making for HR-Positive, HER2-Negative Localized Breast Cancer (10:21) The Role of CDK4/6 Inhibitors in Therapy for HR-Positive Breast Cancer (37:18) Oral Selective Estrogen Receptor Degrad...

Featuring perspectives from Dr Petros Grivas , including the following topics: Collaboration between urologists and medical oncologists for the management of urothelial bladder cancer (UBC) (0:00) Evolution of treatment modalities for non-muscle-invasive bladder cancer (NMIBC) (11:16) Perspective on recurrence mechanisms of NMIBC (22:21) Potential implications of circulating tumor DNA-based resear...

Featuring perspectives from Dr John N Allan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran , including the following topics: Introduction (0:00) First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) (11:44) The Impact of Comorbid Conditions on the Choice of First-Line Therapy for Newly Diagnosed CLL (18:08) Toxicities and Other Practical Considerations with Venetoclax-Based Treatment (25...

Featuring perspectives from Dr William J Gradishar, Dr Virginia Kaklamani, Dr Erica Mayer and Dr Seth Wander , including the following topics: Introduction (0:00) Addition of Ovarian Function Suppression (OFS) to Adjuvant Endocrine Therapy for Premenopausal Patients with Hormone Receptor (HR)-Positive Breast Cancer — Dr Gradishar (4:49) Case: A woman in her mid 20s with HR-positive, HER2-positive...